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Background/aim: Prematurity is a significant risk factor for developing unconjugated hyperbilirubinemia. This study investigated the
current approach to managing hyperbilirubinemia in preterm newborns in Turkey.
Materials and methods: A study-specific questionnaire on the management of jaundice in preterm infants was sent to 100 level III
neonatal intensive care units in Turkey.
Results: Responses were obtained from 84 centers from all regions of Turkey. Of the centers, 75.3% used the Turkish Neonatology
Society guidelines for deciding to start phototherapy, and 24.7% used different guidelines. The monitoring of bilirubin varied among
the participants. Of the participants, 53.6% believed that prophylactic phototherapy was necessary if the infant’s birth weight was below
1000 g. The participants reported 6 cases of kernicterus in preterm infants in recent years.
Conclusion: There is no single standard approach for managing neonatal hyperbilirubinemia in preterm infants in Turkey. Prophylactic
phototherapy for extremely low birth-weight infants might be added to the guidelines for Turkey.
Key words: Hyperbilirubinemia, preterm

1. Introduction
Bilirubin levels increase soon after birth, and neonatal
hyperbilirubinemia is common in newborns. However,
high levels of unconjugated bilirubin can enter the central
nervous system and cause kernicterus. Because early
identification can prevent severe hyperbilirubinemia,
in 2004, the American Academy of Pediatrics (AAP)
Subcommittee on Hyperbilirubinemia published
guidelines for managing hyperbilirubinemia in newborn
infants of ≥35 weeks gestational age (1).
Premature infants develop more significant jaundice
due to poor bowel motility, decreased oral intake,
and immaturity of the hepatic conjugating system.
Consequently, prematurity is a significant risk factor for
developing hyperbilirubinemia, requiring therapy (2,3).
This study investigated the current approach to
managing hyperbilirubinemia among preterm newborns
in Turkey. The results may contribute to national
guidelines for better management and prevention of
hyperbilirubinemia among preterm newborns.
2. Material and methods
We conducted a survey of the management of
hyperbilirubinemia in preterm infants in Turkey. By
* Correspondence: aysetandrcoglu@yahoo.com

email or a letter, 100 clinical directors of level III neonatal
intensive care units (NICUs) in all regions of Turkey in
different hospital types (public, private, teaching, and
university) were invited to complete a questionnaire on the
management of jaundice in preterm infants. After 2 weeks,
all nonresponders were contacted again with second and
third copies of the questionnaire. Another phone call was
made to clinicians who failed to respond to the last call.
The questionnaire examined the approach to preterm
infants with hyperbilirubinemia in NICUs. We asked
the participants about the approaches used to assess
jaundice clinically, monitoring the total serum bilirubin
(TSB), rebound bilirubin measurement, age-specific
phototherapy threshold, and which devices they used to
treat preterm newborns.
3. Results
We received responses from 84 of the 100 hospitals
surveyed. Of these, 21.4% (n = 18) were located in western
Turkey, and 26.2% (n = 22), 20.2% (n = 17), 19% (n = 16),
and 13.1% (n = 11) were in the central, southern, northern,
and eastern parts of Turkey, respectively. Of the centers,
31% were public hospitals, 44% were training or university
hospitals, and 25% were private hospitals.
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Approximately 19,800 infants under 35 gestational
weeks and 5800 extremely preterm newborns were
monitored in the hospitals over the last year. In total,
91.7 % (n = 77) of the participants felt that extremely
preterm infants were at high risk for developing bilirubin
encephalopathy. Of the respondents, 53.6% believed that
prophylactic phototherapy was necessary if the infant’s
birth weight was below 1000 g.
Of the participants, 42.9% stated that phototherapy
was initiated when the TSB concentration reached
the threshold level. An initial TSB measurement was
performed routinely in 50 hospitals (59.5%). In these
centers, the first TSB measurement was done within 6 (n =
13), 12 (n = 5), 12–24 (n = 7), or 24 (n = 25) h. In 40.5% of
the hospitals, routine measurements were not made, and
the first measurement was based on clinical assessment by
the doctors in the unit. The majority of respondents (56%)
sent venous blood samples to their central laboratories
for the first check of bilirubin, and 40% of the centers
measured bilirubin by spectrophotometry in capillary
blood samples. In 22% of the centers, transcutaneous
bilirubinometers were used, although only 4 centers used
these for the first bilirubin check.
Postphototherapy rebound bilirubin was checked
in 27.4%, 27.4%, and 28.6% of the units at 6, 12, and 24
h, respectively. Of the participants, 10.7% considered
rebound bilirubin measurement unnecessary.
Of the centers, 75.3% used the Turkish Neonatology
Society (TNS) guidelines to decide when to start
phototherapy and to perform exchange transfusion,
whereas 24.7% of the centers used different guidelines.
Light-emitting diode (LED) phototherapy was used in
57.1% of the centers, and conventional phototherapy with
fluorescent light sources was used in 14.3%. In 22.6% of
the centers both LED and conventional approaches were
used, and 3.6% of the centers used all devices, including
fiber optics.

The participants reported 6 cases of kernicterus
in preterm infants in recent years. Our questionnaire
included no questions about the etiology or long-term
follow-up of kernicterus cases. We sent e-mails to the
6 centers that reported a case of kernicterus, but only 3
replied. Two patients had ABO incompatibility and one
patient had Rh disease. One patient with ABO disease had
hearing loss at 1 year of age. There was no information on
the long-term follow-up of the other patients.
4. Discussion
Based on this questionnaire study, we concluded that
the management of neonatal jaundice in preterm infants
varies greatly among hospitals in Turkey. Despite the
common belief among participants that unconjugated
hyperbilirubinemia is more dangerous for preterm infants,
there is no universal approach to these vulnerable infants.
The TNS recommendations for the treatment of jaundice in
infants were published in 2002 (Table) (4). These guidelines
suggest that birth weight and postnatal age should be used
to determine TSB thresholds. New guidelines published
in 2014 adopted the AAP hyperbilirubinemia guidelines
for babies of gestation age 35 weeks or older, while the
management of hyperbilirubinemia in preterm infants
was not revised (5). Although most of the centers used
the TSB threshold of the TNS for starting phototherapy,
6 preterm infants still developed kernicterus. There are
no precise data on the prevalence of hyperbilirubinemia
in newborns, and there are no reports on deaths due to
acute bilirubin encephalopathy in the mortality statistics
for Turkey. Although most studies have examined term
and near-term infants, some studies have found that a
few diseases that are common in Turkey (e.g., glucose6-phosphate dehydrogenase (G6PD) deficiency) cause
neonatal jaundice and that the high rate of consanguinity
and consequent high rate of inherited diseases (e.g.,
galactosemia, G6PD deficiency) may also cause the

Table. The Turkish Neonatology Society’s phototherapy and exchange transfusion threshold in newborns of less than 35 weeks
gestational age.*
Birth weight (g)

24–48 h
FT/exchange (mg/dL)

49–72 h
FT/exchange (mg/dL)

>72 h
FT/exchange (mg/dL)

<1000

4/10

5/11

6/12

1000–1499

5/12

7/14

8/16

1500–1999

7/15

9/16

10/17

≥2000

8/17

12/18

14/19

*If risk factors are present, consider phototherapy and exchange transfusion at a TSB level 2 mg/dL lower than those shown. Risk factors:
isoimmune hemolytic disease, G6PD deficiency, perinatal asphyxia, significant lethargy, temperature instability, acidosis, sepsis, and
albumin level of <3.0 g/dL.
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increased incidence of neonatal hyperbilirubinemia.
Additionally, hemolytic hyperbilirubinemia dependent on
Rh incompatibility persists due to disruptions in maternal
prophylaxis (5–10).
A study of the causes of jaundice in hospitalized
infants conducted in southern Turkey reported that 20%
were isoimmunized and 5% had G6PD (6). Another study
conducted in eastern Turkey reported that the cause of
hyperbilirubinemia was Rh incompatibility in 21.4% and
G6PD deficiency in 9% (7).
Based on our results, half of the respondents thought
that prophylactic phototherapy was necessary for extremely
low-birth-weight (ELBW) infants. The National Institute
of Child Health and Human Development (NICHD)
Neonatal Research Network compared the effects of
aggressive and conservative phototherapy in ELBW
infants. The death rate did not differ between the two
treatments, although neurodevelopmental impairment
was reduced significantly in the aggressive phototherapy
group (11). Lasky et al. (12) reported that aggressive
phototherapy in ELBW infants reduced brainstem auditory
evoked response latencies. In our study, almost all of the
participants agreed that LED phototherapy was more
effective. Nevertheless, 14.3% of the participants used only

conventional phototherapy for preterm infants because
they had only conventional phototherapy devices in their
units. Recently, Morris et al. (13) showed that fiber optic
phototherapy devices were associated with a decreased
risk of age-corrected mental development index (MDI)
score of <85 compared with LED phototherapy at 18–22
months, whereas they found an increased risk of MDI of
<85 with conventional phototherapy compared to LED
phototherapy. Furthermore, conventional phototherapy
resulted in increased risks of death and MDI of <85
compared with LED and fiber optic phototherapy.
Rebound bilirubin was not measured in 10.7% of
the hospitals. The few studies that have determined the
incidence and magnitude of the postphototherapy bilirubin
rebound in preterm infants showed that preterm infants
were at the highest risk of postphototherapy neonatal
bilirubin rebounding to clinically significant levels (14,15).
In conclusion, there is no standard approach to the
management of neonatal hyperbilirubinemia in preterm
infants in Turkey. We highlight the importance of
managing neonatal hyperbilirubinemia in preterm infants,
which is generally considered a simple treatment. We also
suggest that prophylactic phototherapy for ELBW infants
might be added to the guidelines for Turkey.
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